Published in Fam Cancer on September 01, 2012
Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int (2013) 1.01
Endoscopic gastric cancer screening and surveillance in high-risk groups. Clin Endosc (2014) 0.92
Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract (2012) 0.86
Current Perspectives on Gastric Cancer. Gastroenterol Clin North Am (2016) 0.82
Gastric Carcinomas in Young (Younger than 40 Years) Chinese Patients: Clinicopathology, Family History, and Postresection Survival. Medicine (Baltimore) (2016) 0.81
Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). Eur J Hum Genet (2013) 0.79
Breast cancer in the young: role of the geneticist. J Thorac Dis (2013) 0.78
Prophylactic Laparoscopic Total Gastrectomy with Jejunal Pouch Reconstruction in Patients Carrying a CDH1 Germline Mutation. J Gastrointest Surg (2015) 0.77
A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer. BMC Med Genomics (2016) 0.76
History, pathogenesis, and management of familial gastric cancer: original study of John XXIII's family. Biomed Res Int (2012) 0.76
CDH1 mutations in gastric cancer patients from northern Brazil identified by Next- Generation Sequencing (NGS). Genet Mol Biol (2016) 0.75
Sequence-based detection of mutations in cadherin 1 to determine the prevalence of germline mutations in patients with invasive lobular carcinoma of the breast. Hered Cancer Clin Pract (2014) 0.75
Familial Gastric Cancers. Oncologist (2015) 0.75
Clinicopathological Features and Survival of Patients with Gastric Cancer with a Family History: a Large Analysis of 2,736 Patients with Gastric Cancer. J Gastric Cancer (2017) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
E-cadherin germline mutations in familial gastric cancer. Nature (1998) 6.72
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol (2010) 6.60
Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut (2001) 4.97
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer (2007) 2.25
CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg (2007) 2.10
Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer (1993) 2.09
High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut (2011) 2.06
Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control (2008) 1.96
Genetic susceptibility and gastric cancer risk. Int J Cancer (2002) 1.94
Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med (2008) 1.62
Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol (2004) 1.59
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed (2005) 1.58
Gastric cancer: new genetic developments. J Surg Oncol (2005) 1.55
The biological model of gastric carcinogenesis. IARC Sci Publ (2004) 1.53
Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology (2009) 1.18
Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer (2010) 1.15
Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer (2004) 1.09
Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med (2011) 1.05
Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut (2011) 1.02
Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Cancer Sci (2009) 1.00
A simple, practical 'swiss roll' method of preparing tissues for paraffin or methacrylate embedding. J Microsc (1987) 1.00
CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. Int J Cancer (2011) 0.98
Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer (2011) 0.97
BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer (2002) 0.94
Molecular and biologic basis of upper gastrointestinal malignancy. Gastric carcinoma. Surg Oncol Clin N Am (2002) 0.94
Prevalence of gastric and duodenal polyps and risk factors for duodenal neoplasm in korean patients with familial adenomatous polyposis. Gut Liver (2011) 0.91
The spectrum of findings in Cowden syndrome. Clin Gastroenterol Hepatol (2010) 0.88
FAP, gastric cancer, and genetic counseling featuring children and young adults: a family study and review. Fam Cancer (2010) 0.82
Clinical cancer genetics: Part I: Gastrointestinal. Am J Clin Oncol (2011) 0.79
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat (2008) 5.52
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet (2008) 4.44
Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol (2013) 3.04
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86
Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol (2012) 2.59
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol (2008) 2.49
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol (2005) 2.42
Planning the human variome project: the Spain report. Hum Mutat (2009) 2.22
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum Mutat (2013) 1.85
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer (2010) 1.83
Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. Gastroenterology (2008) 1.79
Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol (2006) 1.72
Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward - report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology (2013) 1.71
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet (2004) 1.66
Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res (2011) 1.64
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene (2005) 1.62
Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Hum Mutat (2012) 1.61
Additional value of contrast enhanced intraoperative ultrasound for colorectal liver metastases. Eur J Radiol (2007) 1.60
Pregnancy and early-stage melanoma. Cancer (2003) 1.59
Sharing data between LSDBs and central repositories. Hum Mutat (2009) 1.57
Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers. Clin Colorectal Cancer (2004) 1.57
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood (2004) 1.56
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet (2010) 1.54
Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol (2009) 1.53
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood (2011) 1.51
Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol (2007) 1.50
Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2002) 1.50
Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Hum Mutat (2008) 1.44
Gastric conduit staple line after esophagectomy: to oversew or not? J Thorac Cardiovasc Surg (2006) 1.44
The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res (2003) 1.44
Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.43
Fibrin-thrombin coated sealant increases strength of esophagogastric anastomoses in a rat model. J Surg Res (2012) 1.43
Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with fludarabine: effect on tumor microenvironment. Leuk Lymphoma (2011) 1.42
Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev (2007) 1.36
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat (2008) 1.36
Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Hum Mutat (2008) 1.35
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat (2006) 1.34
Laparoscopic total gastrectomy versus open total gastrectomy for cancer: a systematic review and meta-analysis. Surg Endosc (2012) 1.34
Germline copy number variation and cancer risk. Curr Opin Genet Dev (2010) 1.32
Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med (2005) 1.32
Overview of the mutation spectrum in familial exudative vitreoretinopathy and Norrie disease with identification of 21 novel variants in FZD4, LRP5, and NDP. Hum Mutat (2010) 1.31
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
Commentary on the WHO classification of tumors of lymphoid tissues (2008): "Gray zone" lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematop (2009) 1.31
A database to support the interpretation of human mismatch repair gene variants. Hum Mutat (2008) 1.27
The effect of a multimodal fast-track programme on outcomes in laparoscopic liver surgery: a multicentre pilot study. HPB (Oxford) (2009) 1.25
Diagnostic value of routine aqueous contrast swallow examination after oesophagectomy for detecting leakage of the cervical oesophagogastric anastomosis. ANZ J Surg (2008) 1.22
A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res (2009) 1.22
Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat (2010) 1.22
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica (2012) 1.21
Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat (2006) 1.18
Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res (2005) 1.17
Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol (2008) 1.17
Functional analysis helps to clarify the clinical importance of unclassified variants in DNA mismatch repair genes. Hum Mutat (2007) 1.16
Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients. Fam Cancer (2005) 1.15
Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol (2009) 1.15
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res (2014) 1.13
Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol (2008) 1.13
Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn (2008) 1.13
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol (2010) 1.11
Overlap, common features, and essential differences in pediatric granulomatous inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2010) 1.11
Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress. Patient Educ Couns (2006) 1.10
Aortoesophageal fistula successfully treated by endovascular stent-graft. Ann Thorac Surg (2006) 1.10
High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol (2008) 1.10
Capturing all disease-causing mutations for clinical and research use: toward an effortless system for the Human Variome Project. Genet Med (2009) 1.10
Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. Eur J Hum Genet (2011) 1.09
Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol (2006) 1.08
In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys (2004) 1.08
Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat (2011) 1.07
A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships. Psychooncology (2007) 1.07
Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients. Int J Cancer (2011) 1.07
End-to-end versus end-to-side esophagogastrostomy after esophageal cancer resection: a prospective randomized study. Ann Surg (2014) 1.07
Primary lymphoma of the liver - A complex diagnosis. World J Radiol (2012) 1.07
PMS2 involvement in patients suspected of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.07
Revertant somatic mosaicism by mitotic recombination in dyskeratosis congenita. Am J Hum Genet (2012) 1.07
Residual Esophageal Cancer After Neoadjuvant Chemoradiotherapy Frequently Involves the Mucosa and Submucosa. Ann Surg (2015) 1.07
Robot-assisted endoscopic surgery: a four-year single-center experience. Dig Surg (2005) 1.06
Incidence and risk factors of the intraoperative localization failure of nonpalpable breast lesions by radio-guided occult lesion localization: a retrospective analysis of 579 cases: reply. World J Surg (2013) 1.06
A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example. BMC Cancer (2009) 1.05
Efficacy and complications of nasojejunal, jejunostomy and parenteral feeding after pancreaticoduodenectomy. J Gastrointest Surg (2012) 1.05
In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood (2007) 1.04